Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study
Recent data from the TRIBE2 study have failed to suggest a higher magnitude of benefit from upfront FOLFOXIRI/bevacizumab in patients with BRAF-mutant metastatic colorectal cancer (mCRC) as previously reported in the TRIBE study.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Roberto Moretto, Mirella Giordano, Anello M. Poma, Alessandro Passardi, Alessandra Boccaccino, Filippo Pietrantonio, Gianluca Tomasello, Giuseppe Aprile, Sara Lonardi, Veronica Conca, Cristina Granetto, Antonio Frassoldati, Matteo Clavarezza, Alessandro S Tags: Original Research Source Type: research